Amelenodor [CAS 2389235-01-0]

NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis[1][2].

[2389235-01-0]

C24H21N3O3

399.44

CC1=NC(OC2=CC(OC3=CC=CC(C)=N3)=CC(OC4=CC=CC(C)=N4)=C2)=CC=C1

NOD-like Receptor (NLR)

98.11

DMSO : 135 mg/mL (ultrasonic; warming)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature